July 13, 2018, SynoMC participated in the Edinburgh-Shenzhen Smart Innovation Week organized by the Shenzhen Creative Investment Group and Doctorate Association, and supported by the City of Edinburgh Council and the Shenzhen Municipal People’s Government.  During the award ceremony held at the Wardolf Astoria Hotel, Dr Vincent Xie from SynoMC received the First Runner-up Award from the Lord Provost of Edinburgh, Frank Ross, in the 2018 Creat in Edinburgh Competition.  The ceremony was witnessed by the Chinese Consul General in Edinburgh, Mr Xinchun Pan, the Deputy Director of Standing Committee of Bao’an District People’s Congress, Mr Xijin Su, and many other high-ranking delegates.  Dr Xie delivered a talk on ‘Innovative Non-viral Vector for Gene Therapy: Introduction of Minicircle DNA Platforms’, which was well received by representatives from established local institutions including NHS, Creative Edinburgh and the University of Edinburgh.  He went on to spend some time in Scotland to explore business and collaboration opportunities, and there were apparently strong interests from the international research community.

 Apr 4, 2018, SynoMC and Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences hosted an initiation ceremony for the newly set up Joint Laboratory for Bacterium-mediated Minicircle-based Anticancer Gene Therapy.

  Dr Zhi-Ying Chen and Dr Vincent Xie from SynoMC, Mr Ya-Lei Bi and Dr Chen-Li Liu from SIAT, and many others, participated in the ceremony.  Having collaborated successfully and sharing similar goals, the two parties will work closely on the construction of vectors, targeted delivery, new product development, technology platform and training of talents, for bacterium-mediated cancer gene therapy.

Aug 2, 2017, SynoMC and Guiyang Yuyang Trading Co. Ltd. jointly set up a subsidary – Guizhou Zhongze Minicircle Biotechnology Co. Ltd. (abbreviated as Zhongze MC) in Guiyang, Guizhou province.  Zhongze MC is responsible to bring to the market an innovative bispecific antibody minicircle DNA product for the treatment of B-cell lymphoma, providing a safe, effective, convenient, affordable and revolutionary therapeutic option.